This study suggests that in this patient cohort, the WBF is statistically inferior to the conventional ABF. However, our findings also suggest that the WBF may correctly predict TT sizes in a subset of patients in whom the ABF is inaccurate.”
“OBJECTIVE: To estimate the risk of venous thromboembolism, stroke, or myocardial infarction (MI) associated with the use of oral contraceptive pills (OCPs) and to describe how these risks vary by dose or formulation.
DATA SOURCES: We searched PubMed, Smoothened Agonist Embase, the Cochrane Database of Systematic Reviews,
and ClinicalTrials.gov for studies published from January 1995 through June 2012 that evaluated the association between OCP use and risk of venous thromboembolism, stroke, or MI.
METHODS OF STUDY SELECTION: We reviewed 6,476 citations. We included English-language, controlled studies with human participants Ferroptosis inhibitor reporting a quantitative association between exposure to OCPs and outcomes of venous thromboembolism, stroke, or
MI. Two investigators independently reviewed articles for inclusion or exclusion; discordant decisions were resolved by team review and consensus. Random-effects meta-analysis was used to generate summary odds ratios (ORs).
TABULATION, INTEGRATION, AND RESULTS: Fifty studies met inclusion criteria. There were no randomized clinical trials. We found threefold increased odds of venous thromboembolism among current compared with noncurrent OCP users (14 studies; OR 2.97, 95% confidence interval [CI] 2.46-3.59). We found twofold
increased odds of ischemic stroke (seven studies; OR 1.90, 95% CI 1.24-2.91). GSK461364 in vitro There was no evidence of increased risk of hemorrhagic stroke (four studies; OR 1.03, 95% CI 0.71-1.49) or MI (eight studies; OR 1.34, 95% CI 0.87-2.08).
CONCLUSION: Current use of combined OCPs is associated with increased odds of venous thromboembolism and ischemic stroke but not hemorrhagic stroke or MI.”
“Purpose of review
The present review describes the recent experience with kidney transplantation using donation after circulatory determination of death (DCDD) including efforts to expand the potential pool of DCDD donors.
Recent findings
The use of DCDD kidneys represents a growing source of kidneys for transplantation in the USA, although not to the same extent as in Europe. Expansion of the potential donor pool has included the use of kidneys with extended time to donor arrest and pediatric donors. The use of machine perfusion for DCDD kidneys has failed to demonstrate significant benefit.
Summary
DCDD kidneys continue to demonstrate increased rates of delayed graft function and primary nonfunction when compared with kidneys recovered after donation after brain death (DBD) likely due to increased warm ischemic time during recovery.